Ontology highlight
ABSTRACT:
SUBMITTER: Novello S
PROVIDER: S-EPMC6005013 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature
Novello S S Mazières J J Oh I-J IJ de Castro J J Migliorino M R MR Helland Å Å Dziadziuszko R R Griesinger F F Kotb A A Zeaiter A A Cardona A A Cardona A A Balas B B Johannsdottir H K HK Das-Gupta A A Wolf J J
Annals of oncology : official journal of the European Society for Medical Oncology 20180601 6
<h4>Background</h4>This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib.<h4>Patients and methods</h4>ALUR (MO29750; NCT02604342) was a randomized, multicenter, open-label, phase III trial of alectinib versus chemotherapy in advanced/metastatic ALK-positive NSCLC patients previous ...[more]